FDA Brief

Warning letters Drugs

FDA warning letter to

International Medication Systems Limited

High riskIssued Jul 2Posted Jul 14Center for Drug Evaluation and Research (CDER)

FDA found insect larvae and heavy microbial growth in International Medication Systems' sterile filling area; its epinephrine injection lot was later recalled.

What happened

FDA inspected the company's drug manufacturing facility in South El Monte, California, from December 9 to 19, 2025. Investigators found environmental monitoring plates in and next to the ISO 5 aseptic filling area (the cleanest area, where sterile product is exposed) with too-many-to-count bacterial growth and insect larvae, and the company released the epinephrine injection lot made that day. FDA also found the company's investigations, aseptic line design, and a water storage tank with dark-colored buildup to be inadequate; after an FDA teleconference on March 26, 2026, the company voluntarily recalled epinephrine injection USP 0.1 mg/mL lot EA038A5 on April 1, 2026 for lack of sterility assurance.

What FDA found

  1. The company did not properly investigate contamination findings and released a batch even though monitoring plates in the sterile filling area showed heavy bacterial growth and insect larvae.

    21 CFR 211.192
  2. The aseptic filling lines are not built or controlled to prevent contamination: an operator stands inside the cleanest zone and manually cuts open and scoops stoppers, that area was not monitored, and the airflow (smoke) studies were not done properly.

    21 CFR 211.42(c)(10) and 21 CFR 211.113(b)
  3. The water system's storage tank, which also feeds cleaning, was coated inside with dark-colored buildup, had been patched with sealant, and used threaded taped connections instead of sanitary fittings.

    21 CFR 211.63
  4. The quality unit allowed release of a lot made under contaminated conditions instead of rejecting it, so it did not use its authority to protect product quality.

  5. The company relied on passing sterility tests to justify release, although a sterility test alone cannot show that every unit is sterile.

What FDA wants

FDA tells the company to correct the violations promptly and to reply in writing within 15 working days, including third-party assessments and remediation plans for investigations, corrective actions, pest control, aseptic operations and the water system, plus a risk review of batches still within expiry. If corrective actions cannot be finished in that time, the company must explain the delay and give a schedule.

Who should pay attention

  • hospital and clinic buyers of sterile injectables, including epinephrine
  • distributors and repackagers of this firm's sterile drug products
  • quality teams at other firms running aseptic filling lines or buying APIs from this site

This is a summary. Read the original letter on fda.gov.

International Medication Systems Limited's FDA history

Recalls in the last 12 months

Apr 22 Class II International Medication Systems Ltd.
Drug
EPINEPHRINE Injection, USP, 1 mg/10mL (0.1 mg/mL), Rx only, INTERNATIONAL MEDICATION SYSTEMS, LIMITED, So. EL Monte, CA 91733, An Amphastar Pharmaceutical Company, NDC 76329-3318-1
Lack of Assurance of Sterility

Full company page

Similar letters to other companies

  1. CNC Noodle Corporation

    FDA warned CNC Noodle Corporation that its Hayward, California noodle plant had insanitary conditions, no pathogen or allergen controls, and mislabeled products.

    High risk
  2. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  3. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  4. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk